Omalizumab is an anti-IgE monoclonal antibody that was coined to prevent asthma exacerbations in patients with severe allergic asthma. The hypothesis was tested in the EXTRA trial in which Omalizumab was added to patients with severe allergic asthma who were already on ICS and LABA therapy. The results showed 25% relative reduction in asthma exacerbations in patients using Omalizumab compared to placebo. The above visual abstract summarizes the primary findings of the trail.
Want to read more posts?